جستجوی استاد راهنمای دانشگاهی

Didier Trono is a Full Professor at École Polytechnique Fédérale de Lausanne (EPFL), where he leads the Laboratory of Virology and Genetics (LVG) within the School of Life Sciences. Formerly, from 2004 to 2012, he served as the founding dean of EPFL's Faculty of Life Sciences, orchestrating its development and growth during this formative period. Trono received his medical education at the University of Geneva, followed by clinical training in pathology, internal medicine, and infectious diseases in Geneva and at Massachusetts General Hospital in Boston. His scientific career began at the Whitehead Institute of MIT, and in 1990 he was recruited by the Salk Institute of San Diego to launch an AIDS research center. After seven years in the United States, he returned to Europe and eventually joined EPFL. Dr. Trono's research has evolved significantly over his career. Initially focusing on virus-host interactions, he studied pathogens like HIV and Hepatitis B virus, creating HIV-derived genetic transfer tools that are now successfully used in gene therapy. For approximately the last fifteen years, his research has centered on epigenetics, particularly exploring the impact of retroelements and their control mechanisms on development and physiology of higher organisms, including humans. His laboratory investigates how transposable elements and KRAB zinc finger proteins regulate gene expression, with important implications for understanding cancer biology and developing new diagnostic and therapeutic approaches. Analysis of his recent publications (2022-2024) reveals a strong focus on transposable elements, KRAB zinc finger proteins, and their roles in gene regulation and cancer. His work combines molecular biology, genomics, and bioinformatics approaches to understand how these ancient viral remnants have been co-opted by the host genome to regulate development and cellular functions. The research spans basic molecular mechanisms to potential clinical applications in cancer diagnosis and therapy, with some recent work also addressing SARS-CoV-2 and immune responses. Throughout his career, Professor Trono has mentored numerous PhD students, including Bojkowska Karolina, Brandão Sanches Vong Martins Filipe Amândio, Bulliard Yannick, Coluccio Andrea, Corsinotti Andrea, Coudray Alexandre, De Tribolet-Hardy Jonas Caspar, and Dorschel Iris Arianna. His laboratory has received significant funding to support research at the intersection of virology, genetics, and epigenetics, contributing to EPFL's reputation as a leading institution in life sciences research. The Trono Laboratory continues to be at the forefront of research on retroelements and their regulatory mechanisms, maintaining a vibrant research environment that bridges fundamental biological questions with potential medical applications, particularly in cancer research and precision medicine.

• Epigenetics
• Retroelements
• Transposable elements
• +۵ مورد دیگر

Rolf Halden is a Professor and Center Director at Arizona State University, holding appointments in the School of Sustainable Engineering and the Built Environment, the Biodesign Center for Environmental Health Engineering, and the Global Futures Scientists and Scholars program. He is a leading expert in environmental health engineering, wastewater-based epidemiology, and bioremediation. Education: Ph.D. in Civil (Environmental) Engineering, University of Minnesota (1997) M.S. in Civil (Environmental) Engineering, University of Minnesota (1994) M.S. in Biology, Technical University of Braunschweig, Germany (1992) Postdoctoral Fellow, Environmental Science, Lawrence Livermore National Laboratory (1998) Research Focus: Halden’s research integrates environmental chemistry, public health, and sustainability to understand how anthropogenic chemicals affect ecological and human health. His lab uses advanced mass spectrometry (LC-MS/MS, MALDI-TOF) to track pollutants such as PPCPs, microplastics, pesticides, and dioxins across air, water, soil, and biological systems. He pioneered the use of wastewater treatment plants as public health observatories, enabling real-time tracking of disease, drug use, and environmental exposures. Scientific Awards & Recognition: Leadership Award, Arizona State University (2018) Rocky Mountain Emmy Award (2018) Leroy E. Burney Lecturer, Johns Hopkins School of Public Health (2011) ACS Expert Program Member (2014–present) NIEHS Superfund R01 Working Group National Leader (2012–2014) Labs & Teams: Halden is the Founding Director of the Biodesign Center for Environmental Health Engineering at ASU, where he leads a multidisciplinary team focused on environmental proteomics, bioremediation, and diagnostic tool development. He also co-leads the Human Health Observatory , a national wastewater monitoring network. Grants & Funding: Halden has secured major funding from NSF, NIH, EPA, DoD, and private industry. Notable projects include the development of in-situ groundwater monitoring devices, national wastewater surveillance of SARS-CoV-2, and studies on microplastics and neurodegenerative disease.

• Environmental Health Engineering
• Wastewater-Based Epidemiology
• Bioremediation
• +۷ مورد دیگر

Jonas Fischer is the head of the Explainable Machine Learning group at the Max Planck Institute for Informatics, Department of Computer Vision and Machine Learning. His research focuses on interpreting complex machine learning models, particularly in genomics and healthcare, aiming to enhance robustness and alignment with human decision-making. Prior to his role at MPI, he was a postdoctoral fellow at Harvard University's Department of Biostatistics, where he worked on interpretable models for gene regulatory systems in cancer. Education: PhD in Computer Science from Saarland University (2022), with a thesis titled More than the sum of its parts , exploring the intersection of pattern mining and deep learning. He has contributed to advancing methods in neural network pruning, federated learning, and low-dimensional embeddings (e.g., dtSNE, Mercat). His work bridges computational biology, data mining, and machine learning, with applications in DNA methylation analysis, graph-based differential networks, and biomedical informatics. Key research areas include: (1) Explainable AI and neural network interpretability, (2) Biomedical applications of machine learning (e.g., gene regulatory networks, cancer genomics), (3) Low-dimensional embeddings and visualization techniques, (4) Federated learning for privacy-preserving collaborative models, and (5) Pattern mining for error analysis in NLP and classification tasks. Publications span top venues like NeurIPS, ICLR, Bioinformatics, and Genome Biology. His group develops tools such as BONOBO for omics data integration and node2vec2rank for scalable graph analysis. He actively collaborates with biomedical researchers to address challenges in data-driven healthcare and precision medicine.

• Machine Learning
• Explainable AI
• Neural Networks
• +۳ مورد دیگر

Vivek Shenoy is the Eduardo D. Glandt President's Distinguished Professor at the University of Pennsylvania, with primary appointments in the Department of Materials Science and Engineering and secondary appointments in Bioengineering and Mechanical Engineering and Applied Mechanics. He leads the Multiscale Mechanobiology and Biomaterials Laboratory, which focuses on developing theoretical frameworks and numerical methods to understand complex biological and engineering systems across multiple length scales. Shenoy's research spans mechanobiology, chromatin organization, cell mechanics, and biomaterials. His work addresses the fundamental challenge of modeling how small-scale cellular phenomena couple with long-range tissue-level interactions across micrometers to centimeters. By integrating insights from soft matter physics, solid mechanics, chemistry, and applied mathematics, his group develops multiphysics continuum and mesoscale theories to elucidate mechanisms controlling both biological and engineering systems. His recent publications demonstrate an increasing focus on nuclear mechanics, chromatin organization, and the interplay between mechanical forces and gene regulation. Analysis of Shenoy's publication record reveals a strong interdisciplinary approach, with high-impact papers spanning biophysics, materials science, and cell biology. His work shows consistent evolution from fundamental mechanics of materials to complex biological systems, with recent emphasis on the mechanical regulation of chromatin architecture, cell migration dynamics in 3D environments, and mechanotransduction in development and disease. His publications appear regularly in top journals including Nature, Science, and their affiliated publications, demonstrating significant influence across multiple fields. Eduardo D. Glandt President's Distinguished Professor Multiple publications in Nature, Science, and PNAS Active research program with publications through 2025 Shenoy actively mentors students and postdocs through his laboratory, with numerous co-authored publications indicating strong mentorship. His research program appears to be well-funded through multiple grants supporting his work in mechanobiology and biomaterials. The Multiscale Mechanobiology and Biomaterials Laboratory maintains active collaborations across disciplines and institutions, reflecting the interdisciplinary nature of his research. The Multiscale Mechanobiology and Biomaterials Laboratory, housed within the Department of Materials Science and Engineering at the University of Pennsylvania, serves as the primary research hub for Shenoy's work. The lab maintains an active presence on social media (Twitter: @ShenoyLab) for updates on activities and publications. Their research approach combines theoretical modeling with experimental validation to address fundamental questions at the interface of mechanics, materials science, and biology.

• Mechanobiology
• Multiscale Modeling
• Biomaterials
• +۶ مورد دیگر

Alexis Battle is an Associate Professor at Johns Hopkins University with appointments in Biomedical Engineering , Computer Science , and Genetic Medicine (secondary). She directs the Malone Center for Engineering in Healthcare and serves as Deputy Director of the Data Science and AI Institute . Educated at Stanford University (PhD in Computer Science, 2013), Battle transitioned to academia after leadership roles at Google. Research Focus: Battle’s work bridges genomics and machine learning , emphasizing the impact of genetic variation on human health. Her lab develops tools like Watershed to predict functional effects of rare variants, aiming to enhance rare disease diagnosis. Key themes include non-coding DNA analysis , personalized genomics , and systems biology , with applications in cardiovascular disease and neurodegenerative disorders . Publications & Awards: Over 60 peer-reviewed articles in journals like Nature , Science , and Genome Biology , with recent emphasis on single-cell transcriptomics , multiomics integration , and telomere biology . Recipient of the President’s Frontier Award (2022), Microsoft Investigator Fellowship (2019), and Searle Scholar (2016). Scientific Awards: 2022 President’s Frontier Award 2019 Microsoft Investigator Fellowship 2019 Johns Hopkins Discovery Award 2017 Johns Hopkins Catalyst Award 2016 Searle Scholar Advising & Funding: Mentors 11 PhD students, 3 undergraduates, and postdoctoral fellows. Her research is funded by NIH, Searle Scholars, and institutional grants. The Battle Lab collaborates on projects like the GTEx Consortium , focusing on gene regulation and clinical genomics .

• Genomics
• Machine Learning
• Computational Biology
• +۳ مورد دیگر

Dr. Pascal Syren is a **Researcher** and **Resident** at Heidelberg University Hospital (UKHD), affiliated with the **Department of Cardiology, Angiology, and Pulmonology** and the **Heidelberg Center for Cardiac Arrhythmias**. His academic role includes contributing to the **Group of Molecular and Translational Cardiac Electrophysiology**, focusing on epigenetic and molecular mechanisms underlying cardiac arrhythmias and heart failure. He holds a PhD from Heidelberg University (2021) on histone deacetylases' influence in cardiac electrophysiology. **Research Interests**: Cardiac electrophysiology, epigenetic regulation (HDACs), ventricular and atrial arrhythmias, echocardiography, and translational cardiology. His work spans basic science to clinical applications, emphasizing ion channel remodeling and therapeutic targets for heart rhythm disorders. **Awards**: Recipient of the **Ernst & Berta Grimmke Foundation Research Grant (2023–2024)** and **Otto-Hess Scholarship (2017–2018)** from the German Cardiac Society. His research bridges molecular mechanisms with clinical cardiology, with contributions to understanding HDAC2's role in action potential dynamics. **Publications**: Over 8 peer-reviewed articles (2016–2025) in journals like *Basic Research in Cardiology* and *Cells*, focusing on histone deacetylase pathways, atrial fibrillation, and ventricular arrhythmia models. Recent work explores neonatal cardiomyocyte electrophysiology and TREK-1 potassium channels in heart failure. **Affiliations**: Active member of the **German Cardiac Society (DGK)** and **European Society of Cardiology (ESC)**, contributing to interdisciplinary cardiac arrhythmia research at Heidelberg's medical faculty.

• Cardiac Electrophysiology
• Histone Deacetylases
• Ventricular Arrhythmias
• +۳ مورد دیگر

Dr. Giulia Biancon is an Assistant Professor Adjunct in the Department of Medical Oncology and Hematology at Yale School of Medicine. She holds a PhD from the University of Milan (2019) and is a member of the Halene Lab, focusing on RNA biology and hematologic malignancies. Her research combines high-throughput methodologies to study RNA mechanisms in diseases like myeloid leukemias and splicing factor mutations. Education: PhD in Molecular Biology from the University of Milan (2019). Research Interests: RNA splicing, stress granules in cancer, epitranscriptomics, clonal hematopoiesis, and the interplay between genetic mutations and cellular pathways in blood cancers. Awards: 2024 Eclipse Award, 2022 ASH Abstract Achievement Award, and 2022 RNA Society Best Poster Award. Her work has been published in journals like Cell Reports , Blood , and Molecular Cell . Labs/Teams: Principal member of the Halene Lab and coordinator at the Yale Center for RNA Science and Medicine. Collaborates with institutions like the SeroNet network for immunology studies.

• RNA Biology
• Myeloid Malignancies
• Hematology
• +۴ مورد دیگر

James Briscoe is a Senior Group Leader at The Francis Crick Institute in London, where he leads a research group focused on developmental biology and morphogen signaling. He previously held positions at the Medical Research Council's National Institute for Medical Research, which later became part of the Francis Crick Institute. Education: BSc in Microbiology and Virology from the University of Warwick, UK PhD from Imperial Cancer Research Fund/King's College London Postdoctoral training at Columbia University with Thomas Jessell Dr. Briscoe's research focuses on the molecular and cellular mechanisms of graded signaling by morphogens and the role of transcriptional networks in cell fate specification. His laboratory employs a range of experimental and computational techniques using model systems including mouse and chick embryos and embryonic stem cells. His work has significant implications for understanding developmental processes and their relationship to disease. His recent publications demonstrate a continued focus on morphogen gradients, neural tube development, and computational approaches to understanding cell fate decisions. His research increasingly integrates single-cell technologies and computational modeling to unravel the complexities of developmental patterning. Scientific Awards and Honors: EMBO Young Investigator (2001) EMBO Gold Medal (2008) Elected to EMBO (2009) Fellow of the Academy of Medical Sciences (2019) Fellow of the Royal Society (2019) As Editor-in-Chief of the journal Development since 2018, Dr. Briscoe plays a significant role in shaping the field of developmental biology. His leadership extends to mentoring researchers and contributing to scientific policy discussions, as evidenced by his recent publication 'Science under siege: protecting scientific progress in turbulent times.' Dr. Briscoe's laboratory at the Crick Institute is well-equipped with access to advanced facilities including light microscopy, flow cytometry, genomics, and computational resources, enabling a multidisciplinary approach to developmental biology questions.

• Developmental Biology
• Molecular Signaling
• Transcriptional Networks
• +۴ مورد دیگر

Kristian Helin is Chief Executive and President of The Institute of Cancer Research (ICR), London, and a Professor with affiliations at the University of Copenhagen and Memorial Sloan Kettering Cancer Center. He founded/directed the Biotech Research & Innovation Centre (BRIC), Centre for Epigenetics, and Danish Stem Cell Center. His research focuses on epigenetic regulation, cancer biology, and stem cell differentiation. Education: Ph.D. Molecular Biology, University of Copenhagen (1991) M.Sc. Chemical Engineering, Technical University of Denmark (1988) Research Interests: Helin's work deciphers molecular mechanisms in cancer, emphasizing epigenetic drivers (e.g., H3K4/H3K36 methylation), transcriptional control, and therapeutic targeting. His lab identified E2F transcription factors, linked epigenetic dysregulation to leukemia/lymphoma, and develops drugs targeting kinases/epigenetic enzymes. Research spans acute myeloid leukemia, B-cell lymphoma, and solid tumors using CRISPR screens and preclinical models. Publication Trends: Recent articles (2023-2025) focus on epigenetic therapy, chromatin remodeling, and kinase signaling in cancer. Key themes include targeting NSD1/KDM5C/RIOK2 enzymes, combination therapies (EZH2/DOT1L inhibitors), and metabolic regulation in leukemia. Studies bridge basic mechanisms (enhancer regulation, insulator accessibility) with translational applications. Awards: Anders Jahre Prize (2014), ERC Advanced Grant (2011), Novo Nordisk Prize (2008) Memberships: Academia Europaea, Royal Danish Academy, EMBO Leadership: Helin co-founded EpiTherapeutics (acquired by Gilead) and leads the Epigenetics and Cancer lab at ICR. His team investigates AML pathogenesis and chromatin complexes like HUSH/NURF. Grants include ERC funding and innovation prizes.

• Cancer biology
• Epigenetics
• Stem cells
• +۵ مورد دیگر

Prof. Paul Stupple is a Professor of Medicinal Chemistry at Monash University, Australia, with over 20 years' experience in pharmaceutical industry and academia. He holds leadership roles at Canthera Discovery and manages the Australian Translational Medicinal Chemistry Facility. His expertise lies in small molecule drug discovery, particularly targeting cancer therapies and epigenetic regulators. Affiliations: Monash University, Faculty of Pharmacy and Pharmaceutical Sciences Canthera Discovery (Director, Medicinal Chemistry) Education: BA and DPhil in Chemistry from the University of Oxford (1992–1999). Early career at Pfizer as a medicinal chemistry leader, delivering 6 clinical candidates. Key contributions include: Licensing deals with Merck (2016) and Pfizer (2018) for preclinical projects Leading the Cancer Therapeutics CRC's medicinal chemistry program Research Interests: Small molecule drug discovery focused on histone acetyltransferase inhibitors, cancer therapeutics, and epigenetic modulation. Notable projects include development of KAT6A/B inhibitors for ER+ breast cancer and STING agonists for immunotherapy. Grants/Projects: Principal Investigator for major initiatives like MedChem Australia (2023–2028) and drug target identification platforms. Collaborates widely with institutions like WEHI and University of Sydney. Over 28 peer-reviewed publications spanning 1997–2025. Labs/Teams: Oversees the Australian Translational Medicinal Chemistry Facility, a key resource for drug discovery in Australia.

• Small Molecule Drug Discovery
• Cancer Therapeutics
• Pharmaceutical Chemistry
• +۳ مورد دیگر

Dr. Vakil Takhaveev is a Lecturer at ETH Zurich's Department of Health Sciences and Technology, within the Institute of Food, Nutrition and Health. His research focuses on DNA damage mechanisms, aging, cancer, and neurodegeneration, with particular emphasis on developing novel DNA-damage-sequencing methods like click-code-seq and TRABI-Seq . He investigates anticancer drug action (e.g., trabectedin), aging clocks using DNA oxidation profiling, and stress-induced carcinogenesis. His work integrates multi-omics approaches and advanced sequencing techniques. Research Directions: Novel DNA-Damage-Sequencing Methods: Developed click-code-seq and TRABI-Seq for genomic mapping of DNA lesions and repair dynamics. Anticancer Drug Action: Explored mechanisms of trabectedin and other chemotherapeutics, linking DNA repair vulnerabilities to therapy resistance. Aging Clocks: Created DNA oxidation-based biomarkers for biological aging using genome-wide profiling in human and mouse models. Stress-Induced Pathologies: Studies metabolic and DNA damage links to early tumorigenesis and neurodegeneration. Awards & Recognition: 2025 Public Award Winner in PIs of Tomorrow competition 2024 ETH Zurich Career Seed Award Best presentation awards (Swiss Chemical Society, American Chemical Society) Grants & Collaborations: Impetus grants for aging clock development Swiss Chemical Society and American Chemical Society fellowships Labs & Teams: Leads research on DNA damage and aging mechanisms at ETH Zurich, collaborating with international groups in oncology and toxicology.

• DNA Damage and Repair
• Aging Mechanisms
• Cancer Biology
• +۶ مورد دیگر

Andrew Spakowitz is a Professor of Chemical Engineering, Materials Science and Engineering, and by courtesy, Applied Physics and Chemistry at Stanford University. He currently serves as the Senior Associate Dean for Research and Faculty Affairs and holds the Tang Family Foundation Chair of the Department of Chemical Engineering. His academic career at Stanford spans from Assistant Professor (2006-2014) to Associate Professor (2014-2020) and now Professor since 2020. Dr. Spakowitz earned his PhD in 2004, MS in 2001 from the California Institute of Technology, and his BS in Chemical Engineering from the University of Wisconsin, Madison in 1999. He completed postdoctoral training in Molecular and Cell Biology and Biophysics at UC Berkeley from 2004-2006. His research focuses on theoretical and computational approaches to understanding biological processes and complex materials. The Spakowitz lab addresses fundamental chemical and physical phenomena through four main research themes: chromosomal organization and dynamics, protein self-assembly, polymer membranes, and charge transport in conducting polymers. His group employs diverse theoretical and computational methods including analytical theory of semiflexible polymers, polymer field theory, continuum elastic mechanics, Brownian dynamics simulation, equilibrium and dynamic Monte Carlo simulations, and reaction-diffusion modeling. Analysis of his recent publications reveals a strong emphasis on epigenetics and chromatin dynamics, with significant work on DNA methylation patterns, nucleosome clustering, and chromosome organization. His research also extends to polymer physics applications in biological systems, particularly in respiratory diseases, water purification membranes, and bacterial phage interactions with human mucus. Tang Family Foundation Chair of the Department of Chemical Engineering Professor Spakowitz mentors several graduate students and postdoctoral scholars in the Chemical Engineering and Materials Science departments. His lab members work on diverse projects spanning from chromatin dynamics to polymer membranes for water purification. He teaches multiple courses including CHEMENG 120B (Energy and Mass Transport), CHEMENG 340 (Molecular Thermodynamics), CHEMENG 466 (Polymer Physics), and CHEMENG 467 (Physics of Biomacromolecules). The Spakowitz lab operates from Clark S295 at Stanford University, conducting theoretical and computational research that bridges chemistry, physics, biology, and engineering disciplines to address complex problems across multiple length and time scales.

• Chromosomal organization and dynamics
• Protein self-assembly
• Polymer membranes
• +۷ مورد دیگر

Shasha Chong is an Assistant Professor of Chemistry at the California Institute of Technology and a Ronald and JoAnne Willens Scholar. She earned her B.S. from the University of Science & Technology of China (2008) and Ph.D. from Harvard University (2014). Her research bridges chemistry, physics, and biology to investigate the molecular mechanisms of cellular processes, focusing on intrinsically disordered regions (IDRs) in transcription proteins. Research Focus: IDRs in transcriptional regulation, cancer biology, liquid-liquid phase separation, and single-molecule imaging techniques. Grants & Awards: CCE Innovation Award (2024), ALSF Innovation Grant, Mallinckrodt Research Grant, Margaret E. Early Medical Research Trust Grant. Collaborations: Caltech-City of Hope Biomedical Research Initiative Grant (2025). Teaching: Co-instructor for courses like Biochemistry Laboratory (Ch 11) and Advanced Topics in Biochemistry (BMB/Bi/Ch 174). Labs & Teams: Leads the Chong Laboratory at Caltech, focusing on interdisciplinary approaches combining single-molecule imaging, genome editing, and bioinformatics.

• Transcriptional Regulation
• Intrinsically Disordered Proteins
• Single-Molecule Biophysics
• +۴ مورد دیگر

Weiping Tang is a Professor of Pharmaceutical Sciences and Chemistry at the University of Wisconsin-Madison, holding the Janis Apinis Professorship in the School of Pharmacy and the Vilas Distinguished Achievement Professorship. He also serves as Director of the Medicinal Chemistry Center at the School of Pharmacy and maintains a faculty appointment with the Department of Chemistry in the College of Letters and Science. Janis Apinis Professor of Pharmaceutical Sciences Vilas Distinguished Achievement Professor Director of Medicinal Chemistry Center Faculty Appointment with Department of Chemistry Dr. Tang received his B.S. in Chemistry from Peking University in 1997, M.S. in Chemistry from New York University in 1999, Ph.D. in Organic Chemistry from Stanford University in 2005, and completed a postdoctoral fellowship in Medicinal Chemistry, Chemical Biology and Drug Discovery at Harvard University in 2007. Dr. Tang's research program focuses on drug discovery for cancer, infectious diseases, and neurodegenerative disorders through three interconnected areas: Organic Synthesis (advancing glycoscience through novel carbohydrate synthesis technologies), Medicinal Chemistry (developing small molecules that selectively remove disease-associated proteins), and Chemical Biology (dissecting biological pathways using novel small molecule probes). His group operates as an interdisciplinary team where chemists and biologists collaborate closely on drug discovery projects, with particular emphasis on developing novel degraders for disease-causing proteins. Analysis of Dr. Tang's publication record reveals a significant shift toward targeted protein degradation technologies, particularly PROTACs and molecular glues, while maintaining strong foundations in carbohydrate chemistry. His most impactful recent work includes developing degraders for extracellular and membrane proteins (previously considered 'undruggable'), creating rapid synthesis platforms like Rapid-TAC and Rapid-Glue, and advancing understanding of ternary complex formation for novel PROTAC design. His research spans both chemical methodology development and therapeutic applications across multiple disease areas. Vilas Distinguished Achievement Professorship Janis Apinis Professorship Numerous high-impact publications in leading chemistry and pharmacology journals Editor's pick and hot paper designations for significant contributions Dr. Tang mentors a diverse team of graduate students, postdoctoral fellows, and staff scientists with expertise spanning synthetic chemistry, medicinal chemistry, carbohydrate chemistry, computational chemistry, biochemistry, and cell biology. His group has developed innovative platforms for the rapid synthesis of protein degraders and has made significant contributions to understanding the mechanisms of action for these novel therapeutics. Current research includes developing selective degraders for cancer targets like RIPK1, BRD4, and CARM1, as well as advancing delivery systems for clinical translation. The Tang Research Group maintains state-of-the-art facilities within the School of Pharmacy at UW-Madison, equipped for comprehensive chemical synthesis, compound characterization, and biological evaluation. The group actively collaborates with researchers across campus and with industry partners to advance discoveries toward clinical applications, with particular focus on cancer therapeutics and protein degradation technologies.

• Targeted Protein Degradation
• PROTACs
• Medicinal Chemistry
• +۵ مورد دیگر

Britt Adamson is an Associate Professor in the Department of Molecular Biology and the Lewis-Sigler Institute for Integrative Genomics at Princeton University, where she serves as Director of the Undergraduate Program in Quantitative and Computational Biology. Her lab investigates molecular networks in human cells with focus on stress response mechanisms and genome editing technologies. She received her B.S. in Biology from the Massachusetts Institute of Technology (2005) and Ph.D. in Genetics and Genomics from Harvard University (2012), followed by postdoctoral training at UCSF under Jonathan Weissman supported by a Damon Runyon Cancer Research Foundation Fellowship. Adamson's research centers on how cells organize stress response networks during DNA damage and endoplasmic reticulum stress, developing CRISPR-based functional genomics and single-cell sequencing tools to map molecular behaviors. Her work bridges fundamental cell biology with therapeutic applications in genome editing. Analysis of her 15 most recent publications reveals dominant themes in precision genome editing (prime/base editing optimization) and systematic dissection of DNA repair pathways through combinatorial CRISPR screening. Her lab consistently integrates computational approaches with high-resolution experimental techniques to uncover context-dependent cellular behaviors. Her scientific recognitions include: Damon Runyon Cancer Research Foundation Postdoctoral Fellowship Princeton IP Accelerator Award (2025) STAT Who to Know: 10 Scientists leading a new generation of gene editors (2024) Adamson actively mentors eight graduate students (including alumni Ann Cirincione and Jun Hussmann) and two postdocs, with research funded through institutional awards and collaborative grants. Her lab's technological developments have enabled projects spanning virology, immunology, and developmental biology. The Adamson Lab operates within Princeton's Lewis-Sigler Institute for Integrative Genomics, fostering an interdisciplinary environment that merges cell biology, genomics, and computational science. Current projects focus on improving prime editing efficiency and understanding stress response adaptation in disease contexts.

• Stress Response Networks
• DNA Damage Response
• Genome Editing
• +۳ مورد دیگر